Business
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Includes thermostabilized Ebola vaccines MarVax™ and SuVax™Includes nanoemulsion adjuvant compatible with lyophilizationPRINCETON, N.J., April 25, 2024
About this update from Soligenix, Inc.
[{"type":"text","content":"Includes thermostabilized Ebola vaccines MarVax™ and SuVax™Includes nanoemulsion adjuvant compatible with lyophilizationPRINCETON, N.J., April 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of intent to grant additional patents based on its patent application titled \"Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines\" in the United Kingdom and South Africa, with other international jurisdictions pending. The Company has previously announced multiple issued patents within the same patent family in the United States (U.S.). The allowed claims are directed to unique, proprietary compositions and methods related to combinations of glycoprotein antigens with nanoemulsion adjuvants comprising sucrose fatty acid esters prior to lyophilization. The described vaccine platform has previously been successfully applied to mono-, bi- and tri-valent candidates for Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus, including monovalent vaccines SuVax™ (targeting Sudan ebolavirus) and MarVax™ (targeting Marburg marburgvirus).\n\n \n \n \n \n \n \n\n \nThe candidate filovirus vaccines have been previously shown to completely protect non-human primates (NHPs) from subsequent infection, and represent the only recombinant subunit vaccines that have demonstrated efficacy against Zaire ebolavirus and other filoviruses in NHPs. Lyophilization (i.e., freeze drying) of the antigens with bivalent vaccine formulations has also been demonstrated to thermostabilize the antigens at temperatures as high as 40 degrees Celsius (104 degrees Fahrenheit) for up to two years, enabling storage at ambient temperature. No currently licensed lyophilized vaccine that contains an adjuvant is presented in a single vial format and there are few reports of successfully using nanoemulsions in lyophilized formulations. Previous work has demonstrated the use of a single vial platform to co-lyophilize antigen(s) and a nanoemulsion adjuvant, CoVaccine HT™, maintaining key adjuvant stability characteristics including particle size and colloidal stability, as well as maintaining immunogenicity.\n\"Filoviruses such as Zair...